Current Gene Therapy is a bi-monthly peer-reviewed journal aimed at academic and industrial scientists with an interest in major topics concerning basic research and clinical applications of gene and cell therapy of genetic diseases. Cell therapy manuscripts can also include application in non-genetic diseases when cells have been genetically modified. Current Gene Therapy publishes reviews and original research on the latest developments in gene transfer and gene expression analysis, vector development, cellular genetic engineering, animal models and human clinical applications of gene and cell therapy for the treatment of genetic diseases.
Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews and guest edited thematic issues written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
Current Molecular Medicine is an interdisciplinary journal focused on providing the readership with current and comprehensive reviews, original research articles, short communications/letters and drug clinical trial studies on fundamental molecular mechanisms of disease pathogenesis, the development of molecular-diagnosis and/or novel approaches to rational treatment. The reviews should be of significant interest to basic researchers and clinical investigators in molecular medicine. Periodically the journal invites guest editors to devote an issue on a basic research area that shows promise to advance our understanding of the molecular mechanism(s) of a disease or has potential for clinical applications.
Current Pharmaceutical Analysis publishes expert reviews and original research articles on all the most recent advances in pharmaceutical and biomedical analysis. All aspects of the field are represented including drug analysis, analytical methodology and instrumentation. The journal is essential to all involved in pharmaceutical, biochemical and clinical analysis.
Current Pharmacogenomics and Personalized Medicine (CPPM) is a transdisciplinary peer-reviewed biomedical journal that reports new findings and cutting-edge concepts in both pharmacogenomics and personalized medicine under a single cover. CPPM is an accelerator for global personalized medicine and pharmacogenomics. Importantly, the journal provides a multi-disciplinary integrated platform from cell to society to address diagnostics and responsible pharmacogenomics applications in developing countries.
Cytotherapy is the Official Journal of the International Society for Cellular Therapy (ISCT).Cytotherapy publishes cutting edge findings, clinical trials of cell-based therapies, and news and opinion on all aspects of the rapidly expanding field of cell-based treatments for cancer, degenerative disorders, immunotherapy and stem cell transplantation. The journal focuses especially on the practical translation of scientific developments in the laboratory into clinical practice. Cytotherapy is an essential global resource for clinical researchers, oncologists, hematologists, physicians, and regulatory experts involved in cell processing and therapy.The journal's scope includes research in:Stem cell processing and transplantationCell-based therapies of malignant and non-malignant blood diseasesCancerStem cell plasticityAutoimmune diseasesImmunotherapyCongenital disordersNovel molecular therapiesGene therapyMicrovesicle biology and therapeutic application
Dalton Transactions publishes high-quality original research, theoretical and computational studies that significantly advance the field of inorganic chemistry. Its scope includes organometallic, bioinorganic, medicinal inorganic, materials and nanomaterials, with applications including synthesis, catalysis, energy conversion/storage, electrical devices and medicine and sensors.
The Drug Discovery Today reviews collection provides a resource of review content aligning the key output of human molecular medicine with the specific requirements of the drug discovery process. It is designed to systematically cover the essential elements of molecular medicine and drug discovery, in a manner that has relevance to those actually working on the discovery and development of new drugs. This collection will evolve to create a highly structured database and will act as a one-stop-shop for high quality content.Drug Discovery Today: Disease Models discusses the non-human experimental models through which inference is drawn regarding the molecular aetiology and pathogenesis of human disease. It provides critical analysis and evaluation of which models can genuinely inform the research community about the direct process of human disease, those which may have value in basic toxicology, and those which are simply designed for effective expression and raw characterisation.Other titles in this series include:Drug Discovery Today: Disease MechanismsDrug Discovery Today: Therapeutic StrategiesDrug Discovery Today: TechnologiesThere will be four issues each year.The Drug Discovery Today reviews collection is only available online.Ethics in Publishing: General StatementThe Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict.For more information, please refer to: http://www.elsevier.com/wps/find/authorshome.authors/conflictsofinterest
The journal publishes original research reports, authoritative reviews and case reports of experimental and clinical sciences.
EXPERIMENTAL and MOLECULAR MEDICINE, EMM, publishes research papers and a limited number of reviews in the fields of basic and applied molecular biology, and experimental biochemistry in medicine. Research areas include analysis of gene structure, function and regulation; molecular mechanisms of genetic recombination; recombinant nucleic acid technology and gene therapy. EMM is also dedicated to the experimental biochemistry in medicine, including the regulatory mechanisms of body functions; structural biology and interaction between proteins and/or nucleic acids. Although special research areas are emphasized for publication, articles dealing with molecular biology and experimental biochemistry in other areas will also be welcomed.
Expert Opinion on Therapeutic Targets ranks #53 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Therapeutic Targets (ISSN 1472-8222 [print], 1744-7631 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on recently identified novel molecular drug targets, providing expert opinion on the scope for future development and impact on drug discovery.The Editors welcome: * Reviews covering novel disease targets at the molecular level and their implications on future drug development * Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugsThe audience consists of scientists, managers and decision makers in the pharmaceutical industry, and others closely involved in R&D.Read More: http://informahealthcare.com/page/Description?journalCode=ett.
Expert Review of Molecular Diagnostics publishes expert reviews of the latest advancements in the field of molecular diagnostics including the detection and monitoring of the molecular causes of disease that are being translated into groundbreaking diagnostic technologies to be used in the clinical diagnostic setting. Each issue of Expert Review of Molecular Diagnostics contains leading reviews on current and emerging topics relating to molecular diagnostics, subject to a rigorous peer review process; cutting-edge editorials discussing contentious issues in the field; diagnostic profiles featuring independent, expert evaluations of diagnostic tests; meeting reports of recent molecular diagnostics conferences and key paper evaluations reviewing significant, recently published articles carefully selected and assessed by specialists in molecular diagnostic therapy.
Expert Review of Precision Medicine and Drug Development publishes original research and review articles covering the development and clinical application of medicine to be used in a personalized therapy setting. In an era where medicine is recognizing that a one-size-fits-all approach is not always appropriate, it has become necessary to identify patients responsive to treatments and treat patient populations using a tailored approach. Areas covered include:
Expert Review of Vaccines (ISSN 1476-0584) provides expert reviews on the clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines in bioterrorism. All articles are subject to rigorous peer-review.
Extremophiles features original research articles, reviews, and method papers on the biology, molecular biology, structure, function, and applications of microbial life at the edges of survivability. Conditions covered include high or low temperature, pressure, acidity, alkalinity, salinity, or desiccation; or in the presence of organic solvents, heavy metals, normally toxic substances, or radiation.The coverage incorporates aspects of multiple disciplines, including molecular biology, biodiversity, genetics, genomics, metagenomics, proteomics, bioinformatics, survival strategies, macromolecular structure, development, biotechnology, fermentation technology, ultrastructure, biotransformation, metabolism, enzymology, biomembranes, bioenergetics, physiology, cell biology, symbiosis, ecology, bioremediation, methodologies, evolution, phylogeny, taxonomy, astrobiology, and others.Color figures are free in print and online.